UBS Maintains Neutral on Qiagen, Raises Price Target to $50
UBS analyst Dan Leonard maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $48 to $50.
Last updated: 2026-11-19 08:14:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
QIAGEN N.V. (QGEN) operates in the -- sector and is listed on NYSE. The stock is currently priced at $49.56, with a market capitalization of $10.27B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $32.53 to $57.82. This page covers its latest market performance, valuation, price trends and company information.
$10.27B | |
$49.69 | |
$49.75 | |
$49.52 | |
$49.75 | |
3.97M | |
3.67M | |
-- | |
$57.82 | |
$32.53 | |
-- | |
2026-09-30 |
QIAGEN N.V. (QGEN) last closed at $49.56 as of 2026-11-19 00:33:00, down 0.38% ($0.19) from the previous close of $49.75.
During the latest regular trading session, QGEN traded between $49.52 and $49.75, with a volume of 3.97M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, QIAGEN N.V. (QGEN) moved from $50.51 to $49.56, representing a decline of 1.87% ($0.95).
The stock traded between $49.52 and $50.55 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 3.11 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 67.4%
QGEN is currently trading at $49.56, placing it 67.4% of the way from its 52-week low of $32.53 to its 52-week high of $57.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
| Employees | 5,500 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for QIAGEN N.V.
Dividend | |
|---|---|
| Ex-Dividend Date | Jul 7, 2026 |
| Payment Date | Jul 14, 2026 |
| Dividend Per Share | $0.35 |
Latest news related to QIAGEN N.V. and QGEN stock.
UBS analyst Dan Leonard maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $48 to $50.
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.
Eligible investors can buy real shares of QIAGEN N.V. (QGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to QGEN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between QGEN shares and USD.
QGEN Shares to USD
1.00 QGEN shares = 49.563 USD
Calculations are estimates based on the latest available price and are for reference only.